Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Does US FDA Need An Independent Commission To Analyze Its Pandemic Response?

May 21 2021

• By Derrick Gingery

Screenshot from FDLI Annual Conference of former commissioners' discussion — Former FDA commissioners Andrew von Eschenbach, Robert Califf and Mark McClellan discuss how the pandemic changed the agency with FDLI President and CEO Amy Comstock Rick. • Source: Screenshot

Related Content

COVID-19 Should Force ‘Soul Searching’ Over Fragmented US Clinical Trials System, Woodcock Says

Oct 08 2020

After Pandemic, US FDA Commissioner Wants To Continue ‘Rolling Review’ Offered To COVID-19 Products

Oct 13 2020

FDA’s COVID-19 Pandemic Plan Calls For Ongoing Clinical Trial Innovation

Jan 15 2021

For Biosimilars, A Mid-Review Cycle Product Quality Discussion Appears To Be A Bad Omen

Jan 27 2021

A Visual Guide To How FDA Can Manage The Pandemic

Jan 19 2021

PDUFA VII Talks To Begin With COVID-19, Other Familiar Issues To Consider

Jul 21 2020

Moderna’s COVID-19 Vaccine To Get Real-Time Data Assessment By US FDA

Jul 28 2020

CBER’s ‘Courageous’ Coronavirus Guidance Strategy May Catch-On

Jun 26 2020

BIO 2020 Notebook: FDA's Hahn On COVID-19 Lessons To Be Learned; NIH's Fauci On Health Care Disparities; Pfizer's Young On Forgoing Gov't Vaccine Funds

Jun 11 2020

US FDA Urged To Drop Snail Mail For IND Communications

Aug 13 2020

PDUFA VII Could Expand US Real-Time Review Beyond Oncology

Feb 22 2021

Related Companies

Verily

Additional Topics

United States Coronavirus COVID-19 Leadership FDA Regulation Clinical Trials BioPharmaceutical

More from Agency Leadership

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window